Immunitybio (NASDAQ: IBRX) revenue
Immunitybio reported revenue of $113.3m for fiscal 2025, 668.3% more than in fiscal 2024 ($14.7m). Since fiscal 2016 its revenue has grown by 257,372.7%, an average growth of 139.3% a year.
Immunitybio has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2022, −74.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $113.3m | +668.3% | −$256.0m | −226.0% |
| 2024 | $14.7m | +2,270.6% | −$344.2m | −2,334.2% |
| 2023 | $0.6m | +159.2% | −$362.3m | −58,239.5% |
| 2022 | $0.2m | −74.3% | −$351.3m | −146,374.2% |
| 2021 | $0.9m | +54.4% | −$330.3m | −35,361.9% |
| 2020 | $0.6m | −72.5% | −$220.9m | −36,509.1% |
| 2019 | $2.2m | +4,585.1% | −$156.3m | −7,095.9% |
| 2018 | $0.0m | +4.4% | −$98.4m | −209,338.3% |
| 2017 | $0.0m | +2.3% | −$99.1m | −220,266.7% |
| 2016 | $0.0m | — | −$124.5m | −282,954.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Immunitybio revenue compared with its sector
By revenue for its latest fiscal year, Immunitybio ranks 278th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Immunitybio, 668.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 276th | OraSure Technologies | $115.0m | −38.1% |
| 277th | Agenus | $114.2m | 10.4% |
| 278th | Immunitybio | $113.3m | 668.3% |
| 279th | Anika Therapeutics | $112.8m | −5.9% |
| 280th | UroGen Pharma | $109.8m | 21.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Immunitybio
- How much revenue did Immunitybio make in fiscal 2025?
- Immunitybio reported revenue of $113.3m for fiscal 2025, compared with $14.7m in fiscal 2024.
- How much has the revenue of Immunitybio grown?
- Between fiscal 2016 and fiscal 2025 it went from $0.0m to $113.3m: 257,372.7% more, an average growth of 139.3% a year.
- What was the best year for revenue at Immunitybio?
- Of its last 10 fiscal years, fiscal 2025, with $113.3m.
- Where does Immunitybio rank in its sector by revenue?
- It ranks 278th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Immunitybio come from?
- From the annual report (Form 10-K) that Immunitybio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Immunitybio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Immunitybio: the Immunitybio page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.